Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05768919 | Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas | recruiting | Phase 1 / Phase 2 | 30 | SignPath Pharma, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06709417 | A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS) | recruiting | Phase 2 | 52 | Shanghai Chest HospitalOTHER | 1 | Nov 29, 2024 |
| clinicaltrials |
| NCT06709885 | HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer | recruiting | Phase 2 | 100 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06211114 | Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma | recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06538896 | Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study | recruiting | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06704555 | Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06706713 | Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer | recruiting | Phase 2 | 200 | BeBetter Med IncINDUSTRY | 1 | Nov 26, 2024 | clinicaltrials |
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | recruiting | Phase 1 / Phase 2 | 358 | GI Innovation, Inc.INDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT06702826 | Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases | recruiting | Phase 2 | 20 | Rongrong ZhouOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT04741945 | Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS | recruiting | Phase 2 | 40 | Kirsten GrønbækOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT03812874 | A Study of PTX-9908 Injection for Non-resectable HCC with TACE | recruiting | Phase 1 / Phase 2 | 50 | TCM Biotech International Corp.INDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05738434 | Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC | recruiting | Phase 2 | 188 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06698484 | To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)(CAR-T for NHL) | recruiting | Phase 2 | 20 | National University of MalaysiaOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06698965 | Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin | recruiting | Phase 2 | 52 | Shanghai Chest HospitalOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05806099 | A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL | recruiting | Phase 1 / Phase 2 | 132 | Beijing Mabworks Biotech Co., Ltd.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06301399 | Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06566586 | A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma | recruiting | Phase 2 | 80 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06160206 | Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma | recruiting | Phase 2 | 134 | Academic and Community Cancer Research UnitedOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06393985 | Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06632262 | A Phase 2 Clinical Study of ABSK061 and ABSK043 | recruiting | Phase 2 | 202 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05910801 | Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma(V-MIND) | recruiting | Phase 2 | 100 | Academic and Community Cancer Research UnitedOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06269211 | Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression(TOPLINE) | recruiting | Phase 2 | 29 | Ruijin HospitalOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06313190 | Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)(HSBRT2402) | recruiting | Phase 2 | 140 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06639347 | A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma | recruiting | Phase 1 / Phase 2 | 90 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06674096 | RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL | recruiting | Phase 2 | 44 | Zhejiang Cancer HospitalOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT04787042 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | recruiting | Phase 1 / Phase 2 | 316 | Simcha IL-18, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06690697 | Combination of Toripalimab and JS004 Therapy for ccRCC | recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06240143 | Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma(MARIANE) | recruiting | Phase 1 / Phase 2 | 96 | The Netherlands Cancer InstituteOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06612281 | Evaluation of Gixam's Performance in a FIT Negative Population | recruiting | Phase 2 | 400 | Jubaan Ltd.INDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06686043 | HPV Vaccine, Imiquimod, and Metformin Combination Trial(HPV-VIM) | recruiting | Phase 2 | 85 | Baylor College of MedicineOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT06420063 | Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML(BAH244) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06420076 | Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells(BAH246) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06532812 | TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer(BAH249) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06589778 | A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 124 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06684600 | Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 35 | Peking UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06341764 | Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma | recruiting | Phase 2 | 38 | National Cancer Institute, NaplesOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06388031 | ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI | recruiting | Phase 2 | 27 | Peking Union Medical College HospitalOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06677944 | Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer | recruiting | Phase 2 | 47 | Yonsei UniversityOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05254171 | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer(ASPIRE) | recruiting | Phase 2 / Phase 3 | 600 | Panbela Therapeutics, Inc.INDUSTRY | 10 | Nov 6, 2024 | clinicaltrials |
| NCT06530303 | Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer(BAH248) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06608732 | Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission. | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06640582 | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06675201 | Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 165 | Sichuan UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05435248 | Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) | recruiting | Phase 1 / Phase 2 | 354 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05503134 | Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML(KARMA) | recruiting | Phase 1 / Phase 2 | 20 | Nationwide Children's HospitalOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05911958 | A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer | recruiting | Phase 2 | 66 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06667154 | Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy | recruiting | Phase 2 | 33 | Aline Fusco Fares, MDOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT05468242 | Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy | recruiting | Phase 2 | 116 | Sun Yat-sen UniversityOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06664996 | Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT | recruiting | Phase 2 | 33 | West China HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 29, 2024source: clinicaltrials